Ranking of concern, based on environmental indexes, for pharmaceutical and personal care products: An application to the Spanish case

Journal of Environmental Management

Volumn 129, Issue , 2013, Pages 384-397

  Ortiz de García, Sheyla ^a,b   Pinto, Gilberto Pinto ^b   García Encina, Pedro A ^a   Mata, Rubén Irusta ^a  

^a UNIVERSITY OF VALLADOLID   (Spain)

^b UNIVERSIDAD DE CARABOBO   (Venezuela)

Author keywords

Bioaccumulation; Occurrence; Persistence; Pharmaceutical and personal care products; Ranking; Toxicity

Indexed keywords

ALPRAZOLAM; AMOXICILLIN; AZITHROMYCIN; BIOLOGICAL PRODUCT; BROMAZEPAM; CEFACLOR; CIPROFLOXACIN; CLARITHROMYCIN; ENALAPRIL; ERYTHROMYCIN; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; GABAPENTIN; GALAXOLIDE; IRBESARTAN; LEVOFLOXACIN; LORAZEPAM; MOXIFLOXACIN; NORFLEROXACIN; PARACETAMOL; PAROXETINE; PHARMACEUTICAL AND PERSONAL CARE PRODUCT; PREGABALIN; SERTRALINE; SULFAMETHOXAZOLE; TONALIDE; TOPIRAMATE; TRIMETHOPRIM; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; VALSARTAN;

DECISION ANALYSIS; DRUG; ENVIRONMENTAL IMPACT; ENVIRONMENTAL RISK; LIPID; METABOLITE; PHARMACEUTICAL INDUSTRY; QUANTITATIVE ANALYSIS; TOXICOLOGY;

AQUATIC ENVIRONMENT; AQUATIC SPECIES; ARTICLE; BIOACCUMULATION; CHLORINATION; DRUG CLASSIFICATION; DRUG INDUSTRY; ENVIRONMENTAL IMPACT; FOOD WEB; LIPID BLOOD LEVEL; PHYSICAL CHEMISTRY; QUANTITATIVE STRUCTURE ACTIVITY RELATION; QUANTITATIVE STUDY; SEWAGE TREATMENT PLANT; WASTE WATER MANAGEMENT;

SPAIN;

(Q)SARS; ATC; B; BCF; BIOACCUMULATION; BIOCONCENTRATION FACTOR; BIOWIN™; CAS; CHEMICAL ABSTRACTS; CHRONIC TOXICITY; CHV; DART; DECISION ANALYSIS BY RANKING TECHNIQUES; ECOSAR; EMEA; ENVIRONMENTAL RISK ASSESSMENT; EPA EPI SUITE™; ERA; ESTIMATION PROGRAMS INTERFACE SUITE™ DEVELOPED BY THE EPA'S OFFICE OF POLLUTION PREVENTION TOXICS AND SYRACUSE RESEARCH CORPORATION; EUROPEAN MEDICINES AGENCY; EUROPEAN REGULATION FOR REGISTRATION EVALUATION AUTHORIZATION AND RESTRICTION OF CHEMICALS; LC; LEVEL OF CONCERN; NO-OBSERVED EFFECT CONCENTRATION; NOEC; NON-STEROIDAL ANTI-INFLAMMATORY DRUGS; NSAIDS; O; OCCURRENCE; OECD; ORGANIZATION FOR ECONOMIC CO-OPERATION AND DEVELOPMENT; P; PARTIAL ORDER RANKING; PCPS; PECS; PERS; PERSISTENCE; PERSONAL CARE PRODUCTS; PHACS; PHARMACEUTICAL AND PERSONAL CARE PRODUCTS; PHARMACEUTICALLY ACTIVE COMPOUNDS; PHYSICAL-CHEMICAL PROPERTY ESTIMATION ROUTINES; PNEC; POR; PPCPS; PREDICTED ENVIRONMENTAL CONCENTRATIONS; PREDICTED NO EFFECT CONCENTRATION; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIPS; RANKING; REACH; SARS; SIMPLIFIED MOLECULAR INPUT LINE ENTRY SYSTEM; SMILES; SOFTWARE BY US EPA FOR ESTIMATES PROBABILITY OF RAPID AEROBIC AND ANAEROBIC BIODEGRADATION; SRC; STRUCTURE-ACTIVITY RELATIONSHIPS; SYRACUSE RESEARCH CORPORATION; T; THERAPEUTIC CHEMICAL CLASSIFICATION SYSTEM; TOXICITY; UNITED STATES ENVIRONMENTAL PROTECTION AGENCY; US EPA; US EPA ECOLOGICAL STRUCTURE-ACTIVITY RELATIONSHIP; WASTEWATER TREATMENT PLANT; WWTP;

DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; ENVIRONMENTAL MONITORING; HOUSEHOLD PRODUCTS; MODELS, THEORETICAL; PHARMACEUTICAL PREPARATIONS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; SPAIN; WATER POLLUTANTS, CHEMICAL;

EID: 84883341032     PISSN: 03014797     EISSN: 10958630     Source Type: Journal    
DOI: 10.1016/j.jenvman.2013.06.035     Document Type: Article

References (64)

1. Anca F., Gravilescu M. Pharmaceuticals, personal care products and endocrine disrupting agents in the environment - a review. Clean 2009, 37:277-303.
2. Arnot J.A., Gobas F.A.P.C. Areview of bioconcentration factor (BCF) and bioaccumulation factor (BAF) assessments for organic chemicals in aquatic organisms. Environ. Rev. 2006, 4:257-297.
3. Besse J.P., Garric J. Progestagens for human use, exposure and hazard assessment for the aquatic environment. Environ. Pollut. 2009, 157:3485-3494.
4. Boethling R.S., Howard P.H., Meylan W., Stiteler W., Beaumann J., Tirado N. Group contribution method for predicting probability and rate of aerobic biodegradation. Environ. Sci. Technol. 1994, 28:459-465.
5. Bound J.P., Voulvoulis N. Pharmaceuticals in the aquatic environment--a comparison of risk assessment strategies. Chemosphere 2004, 56:1143-1155.
6. Brack W., Bakker J., Deckere E., Deerenberg C., Van Gils J., Hein M., et al. MODELKEY. Models for assessing and forecasting the impact of environmental key pollutants on freshwater and marine ecosystems and biodiversity. Environ. Sci. Pollut. Res. 2005, 12:252-256.
7. Brausch J.M., Rand G.M. Areview of personal care products in the aquatic environment: environmental concentrations and toxicity. Chemosphere 2011, 82:1518-1532.
8. Bruce G.M., Pleus R.C., Snyder S.A. Toxicological relevance of pharmaceuticals in drinking water. Environ. Sci. Technol. 2010, 44:5619-5626.
9. Calamari D., Zuccato E., Castiglioni S., Bagnati R., Fanelli R. Strategic survey of therapeutic drugs in the rivers Po and Lambro in Northern Italy. Environ. Sci. Technol. 2003, 37:1241-1248.
10. Carlsson C., Johansson A., Alvan B., Bergman K., Kuhler T. Are pharmaceuticals potent environmental pollutants? part I: environmental risk assessments of selected active pharmaceutical ingredients. Sci. Tot. Environ. 2006, 364:67-87.
11. Celiz M.D., Tso J., Aga D.A. Pharmaceutical metabolites in the environment: analytical challenges and ecological risks. Environ. Toxicol. Chem. 2009, 28:2473-2484.
12. Cooper E.R., Siewicki T.C., Phillips K. Preliminary risk assessment database and risk ranking of pharmaceuticals in the environment. Sci. Tot. Environ. 2008, 398:26-33.
13. Coutu S., Rossi L., Barry D.A., Chèvre N. Methodology to account for uncertainties and tradeoffs in pharmaceutical environmental hazard assessment. J.Environ. Manage. 2012, 98:183-190.
14. Cronin M.T.D., Jaworska J.S., Walker J.D., Comber M.H.I., Watts C.D., Worth A. Use of QSARs in international decision-making frameworks to predict health effects of chemical substances. Environ. Health Persp. 2003, 111:1391-1401.
15. Cunningham V.L., Constable D.J.C., Hannah R.E. Environmental risk assessment of paroxetine. Environ. Sci. Technol. 2004, 38:3351-3359.
16. Daughton C.G., Brooks B.W. Active Pharmaceutical Ingredients and Aquatic Organisms 2010, Available online at:, (accessed 19.12.12.). http://www.epa.gov/esd/bios/daughton/APIs-aquaticbiota.pdf.
17. Daughton C.G., Ternes T.A. Pharmaceuticals and personal care products inthe environment: agents of subtle change?. Environ. Health Persp. 1999, 107:907-938.
18. Dévier M.H., Mazellier P., Aït-Aïssa S., Budzinski H. New challenges in environmental analytical chemistry: identification of toxic compounds in complex mixtures. CR Chim. 2011, 14:766-779.
19. Doerr-MacEwen N.A., Haight M.E. Expert stakeholders' views on the management of human pharmaceuticals in the environment. Environ. Manage. 2006, 38:853-866.
20. Escher B.I., Fenner K. Recent advances in environmental risk assessment of transformation products. Environ. Sci. Technol. 2011, 45:3835-3847.
21. European Medicines Agency Guideline on the Environmental Risk Assessment of Medicinal Products for Human Use 2006, Doc. Ref.EMEA/CHMP/SWP/4447/00 corr 1*. London.
22. European Parliament and Council Regulation (EC) N° 1907/2006 of 18 December 2006 Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH), Establishing a European Chemicals Agency, Amending Directive 1999/45/EC and Repealing Council Regulation (EEC) No 793/93 and Commission Regulation (EC) No 1488/94 as Well as Council Directive 76/769/EEC and Commission Directives 91/155/EEC, 93/67/EEC, 93/105/EC and 2000/21/EC. Official Journal of the European Union 2006, N° 396 of 30.12.2006.
23. Fatta-Kassinos D., Meric S., Nikolaou A. Pharmaceutical residues in environmental waters and wastewater: current state of knowledge and future research. Anal. Bioanal. Chem. 2011, 399:251-275.
24. Fent K., Weston A.A., Caminada D. Ecotoxicology of human pharmaceuticals. Aquat. Toxicol. 2006, 76:122-159.
25. Freidig A.P., Dekkers S., Verwei M., Zvinavashe E., Bessems J.G.M., Van de Sandt J.J.M. Development of a QSAR for worst case estimates of acute toxicity of chemically reactive compounds. Toxicol. Lett. 2007, 170:214-222.
26. Gagné F., Blaise C., André C. Occurrence of pharmaceutical products in a municipal effluent and toxicity to rainbow trout (Oncorhynchus mykiss) hepatocytes. Ecotox. Environ. Safe 2005, 64:329-336.
27. Gao L., Shi Y., Li W., Liu J., Cai Y. Occurrence, distribution and bioaccumulation of antibiotics in the Haihe River in China. J.Environ. Monit. 2012, 14:1248-1255.
28. Ginebreda A., Muñoz I., López de Alda M., Brix M., López-Doval J., Barceló D. Environmental risk assessment of pharmaceuticals in rivers: relationships between hazard indexes and aquatic macroinvertebrate diversity indexes in the Llobregat River (NE Spain). Environ. Int. 2010, 36:153-162.
29. Granger Morgan M., McFarland (Chairs) M.J. Science Advisory Board (SAB) Review of the Estimation Programs Interface Suite (EPI Suite™). EPA-SAB-07-011 2007, Available online at:, (accessed 18.07.12.). http://www.epa.gov/sab/pdf/sab-07-011.pdf.
30. Gros M., Petrović M., Ginebreda A., Barceló D. Removal of pharmaceuticals during wastewater treatment and environmental risk assessment using hazard indexes. Environ. Int. 2010, 36:15-26.
31. Hereber T. Occurrence, fate, and removal of pharmaceutical residues in the aquatic environment: a review of recent research data. Toxicol. Lett. 2002, 131:5-17.
32. Homem V., Alves A., Santos L. Amoxicillin degradation at ppb levels byFenton's oxidation using design of experiments. Sci. Tot. Environ. 2010, 408:6272-6280.
33. Howard P.H., Boethling R.S., Stiteler W.M., Meylan W.M., Hueber A.E., Beauman J.A., Larosche M.E. Predictive model for aerobic biodegradability developed from a file of evaluated biodegradation data. Environ. Toxicol. Chem. 1992, 11:593-603.
34. Jean J., Perrodin Y., Pivot C., Trepo D., Perraud M., Droguet J., Tissot-Guerraz F., Locher F. Identification and prioritization of bioaccumulable pharmaceutical substances discharged in hospital effluents. J.Environ. Manage. 2012, 103:113-121.
35. Kumar A., Xagoraraki I. Pharmaceuticals, personal care products and endocrine-disrupting chemicals in U.S. surface and finished drinking waters: a proposed ranking system. Sci. Tot. Environ. 2010, 408:5972-5989.
36. Kümmerer K. The presence of pharmaceuticals in the environment due to human use - present knowledge and future challenges. J.Environ. Manage. 2009, 90:2354-2366.
37. Kümmerer K., Al-Ahmad A. Estimation of the cancer risk to humans resulting from the presence of cyclophosphamide and ifosfamide in surface water. Environ. Sci. Pollut. Res. 2010, 17:486-496.
38. Lerche D., Brüggemann R., Sørensen P., Carlsen L., Nielsen O.J. Acomparison of partial order technique with three methods of multi-criteria analysis for ranking of chemical substances. J.Chem. Inf. Comput. Sci. 2002, 42:1086-1098.
39. Liebig M., Moltmann J., Knacker T. Evaluation of measured and predicted environmental concentrations of selected human pharmaceuticals and personal care products. Environ. Sci. Pollut. Res. 2006, 13:110-119.
40. Mayo-Bean K.E., Vince Nabholz J., Meylan W., Howard P.H. User's Guide for ECOSAR Class Program MS-windows Version 1.00 2009, U.S. Environmental Protection Agency.
41. Meylan W., Boethling R.S., Aronson D., Howard P., Tunkel J. Chemical structure-based predictive model for methanogenic anaerobic biodegradation potential. Environ. Toxicol. Chem. 2007, 26:1785-1792.
42. Murray K.E., Thomas S.M., Bodour A.A. Prioritizing research for trace pollutants and emerging contaminants in the freshwater environment. Environ. Pollut. 2010, 158:3462-3471.
43. National Center for Biotechnology Information PubChem Compound Database 2011, Available online at:, (accessed 26.03.12.). http://pubchem.ncbi.nlm.nih.gov/.
44. Nikolaou A., Meric S., Fatta D. Occurrence patterns of pharmaceuticals in water and wastewater environments. Anal. Bioanal. Chem. 2007, 387:1225-1234.
45. Ortiz S.A., Irusta R., Garcia P., Pinto G. Consumption and occurrence of pharmaceutical and personal care products in the aquatic environment in Spain. Sci. Tot. Environ. 2013, 444:451-465.
46. Pavan M., Worth A.P. Review of QSAR Models for Ready Biodegradation 2006, European Commission. Directorate - General Joint Research Centre Scientific and Technical Reports, Institute for Health and Consumer Protection, Available online at:, (accessed 04.04.12.). http://ihcp.jrc.ec.europa.eu/our_labs/computational_toxicology/doc/QSAR_Review_Biodegradation.pdf.
47. Pavan M., Worth A.P. Comparison of the COMMPS Priority Setting Scheme with Total and Partial Algorithms for Ranking of Chemical Substances 2007, European Chemical Bureau, Available online at:, (accessed 25.02.13.). http://ihcp.jrc.ec.europa.eu/our_labs/predictive_toxicology/information-sources/qsar-document-area/Ranking_of_COMMPS_substances.pdf.
48. Pavan M., Worth A.P. ASet of Case Studies to Illustrate the Applicability of DART (Decision Analysis by Ranking Techniques) in the Ranking of Chemicals 2008, European Commission report EUR23481 EN, Office for Official Publications of the European Communities, Luxembourg, Available online at:, (accessed 26.03.12.). http://ihcp.jrc.ec.europa.eu/our_labs/computational_toxicology/doc/EUR_23481_EN.pdf.
49. Petrović M., Solé M., López de Alda M.J., Barceló D. Endocrine disruptors in sewage treatment plants, receiving river waters, and sediments: integration of chemical analysis and biological effects on feral carp. Environ. Toxicol. Chem. 2002, 21:2146-2156.
50. Quintana J.B., Weiss S., Reemtsma T. Pathways and metabolites of microbial degradation of selected acidic pharmaceutical and their occurrence in municipal wastewater treated by a membrane bioreactor. Wat. Res. 2005, 39:2654-2664.
51. Radke M., Lauwigi C., Heinkele G., Mürdter T.E., Letzel M. Fate of the antibiotic Sulfamethoxazole and its two major human metabolites in a water sediment test. Environ. Sci. Technol. 2009, 43:3135-3141.
52. Redshaw C.H., Cooke M.P., Talbot H.M., McGrath S., Rowland S.J. Low biodegradability of fluoxetine HCl, diazepam and their human metabolites in sewage sludge-amended soil. J.Soil Sediment 2008, 8:217-230.
53. Sanderson H., Brain R.A., Johnson D.J., Wilson C.J., Solomon K.R. Toxicity classification and evaluation of four pharmaceuticals classes: antibiotics, antineoplastics, cardiovascular, and sex hormones. Toxicol. 2004, 203:27-40.
54. Sanderson H., Johnson D.J., Reitsma T., Brain R.A., Wilson C.J., Solomon K.R. Ranking and prioritization of environmental risks of pharmaceuticals in surface waters. Regul. Toxicol. Pharm. 2004, 39:158-183.
55. Santos L.H., Araújo A.N., Fachini A., Pena A., Delerue-Matos C., Montenegro M.C.B.S.M. Ecotoxicological aspects related to the presence of pharmaceuticals in the aquatic environment. J.Hazard. Mat. 2010, 175:45-95.
56. SRC PhysProp Database 2010, Available online at:, (accessed 04.04.12.). http://www.srcinc.com/what-we-do/databaseforms.aspx%3fid%3d386.
57. Stockholm County Council Environmentally Classified Pharmaceuticals 2012, Available online at:, (accessed 29.11.12.). http://www.janusinfo.se/Global/Miljo_och_lakemedel/miljobroschyr_engelsk_2012_uppslag.pdf.
58. Streck G. Chemical and biological analysis of estrogenic, progestagenic and androgenic steroids in the environment. Trend. Anal. Chem. 2009, 28:635-652.
59. TALETE srl DART-decision Analysis by Ranking Techniques (Version 2.0) 2007, Available online at:. http://www.talete.mi.ti.
60. Ternes T., Bonerz M., Schmidt T. Determination of neutral pharmaceuticals in wastewater and rivers by liquid chromatography-electrospray tandem mass spectrometry. J.Chrom. A. 2001, 938:175-185.
61. Tunkel J., Howard P.H., Boethling R.S., Stiteler W., Loonen H. Predicting ready biodegradability in the Japanese ministry of international trade and industry test. Environ. Toxicol. Chem. 2000, 19:2478-2485.
62. United States National Library of Medicine ChemID Plus Lite 2010, Available online at:, (accessed 04.04.12.). http://chem.sis.nlm.nih.gov/chemidplus/chemidlite.jsp.
63. ® Windows, V. 4.00 2009, United States Environmental Protection Agency, Washington, DC, USA.
64. Voigt K., Brueggemann R. Ranking of pharmaceuticals detected in the environment: aggregation and weighting procedures. Comb. Chem. High. T. Scr. 2008, 11:770-782.